Clarity Pharmaceuticals ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

More and more thoracic CT scans are being performed worldwide in order to detect lung diseases such as bronchial carcinoma ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.

When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non ...

A groundbreaking technology designed to attack lung tumors and shorten recovery times for patients is now available at St.

Some tumors contain cells that are both SCLC and a form of NSCLC (often large cell), according to the GO 2 for Lung Cancer foundation. (1) Doctors must know the type of cancer you have to ...

Despite years of warnings and a mountain of scientific evidence linking smoking to lung cancer, there remains one confounding question: Why do some smokers never get lung cancer? It’s a puzzle ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, AbbVie is advancing its solid tumor ambitions with a new FDA green light.